Pure Global
NCT05867693

Palmitoylethanolamide and Polydatin in Pediatric Irritable Bowel Syndrome

Palmitoylethanolamide and Polydatin in Pediatric Irritable Bowel Syndrome: a Randomized Controlled Trial
University of Roma La Sapienza·ClinicalTrials.gov·dietary supplementRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Irritable Bowel Syndrome
Drug/Device/Intervention
palmithoylethanolamide/polydatin
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
University of Roma La Sapienza
Location
Roma, Italy
Timeline & enrollment
Phase
N/A
Start date
Apr 19, 2023
End date
Apr 19, 2024
Enrollment
70 participants
Primary outcome

Change in the abdominal pain symptoms

Summary

This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to
 study the efficacy and safety of co-micronised palmithoylethanolamide/polydatin in pediatric
 patients ( 10 years) with Irritable bowel syndrome (IBS)

ICD-10 classifications
Irritable bowel syndromeOther and unspecified irritable bowel syndromeIrritable bowel syndrome with mixed bowel habits [IBS-M]Irritable bowel syndrome with predominant constipation [IBS-C]Irritable bowel syndrome with predominant diarrhoea [IBS-D]
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05867693
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05867693 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Roma La Sapienza and is currently Recruiting. The study focuses on Irritable Bowel Syndrome. Target enrollment is 70 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.